Newsletter Tool

Today’s Big News

Jun 24, 2025

Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates

Rivus’ weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b

Royalty signs off on $2B to bankroll Revolution's RAS cancer drug's road to regulators

Investors sweet on Nektar as phase 2b eczema success doubles share price

Stuart sees dry eye disease drug fail phase 3 tear test, plans another study

With competitive pivotal data, Nuvalent eyes FDA rolling submission in crowded lung cancer niche

BrightGene tops Novo drug in diabetes ahead of Zepbound showdown

UK lays out strategy to become a top 3 life sciences economy by 2035

FDA's acting CDER head Corrigan-Curay heads for the exit amid period of heavy turnover: reports

Featured

Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates

By Zoey Becker

The company noted high rates of discontinuation due to gastrointestinal events, such as vomiting, in fixed-dose arms of its phase 2 trial.

Rivus’ weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

By James Waldron

Rivus’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the drug's obesity potential.

MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b

By Nick Paul Taylor

MindRank has shared the skinny on its oral GLP-1 receptor agonist, publishing data from a Chinese phase 2b obesity trial that suggests efficacy is in the same ballpark as Eli Lilly’s orforglipron.

Royalty signs off on $2B to bankroll Revolution's RAS cancer drug's road to regulators

By James Waldron

Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.

Investors sweet on Nektar as phase 2b eczema success doubles share price

By Nick Paul Taylor

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. The biotech reported a phase 2 win for rezpegaldesleukin in atopic dermatitis, sending its stock up 119% despite the data falling short of the bar set by Regeneron and Sanofi’s Dupixent.

Stuart sees dry eye disease drug fail phase 3 tear test, plans another study

By James Waldron

Stuart Therapeutics’ dry eye disease drug has failed to demonstrate it can increase tear production in a phase 3 test.

With competitive pivotal data, Nuvalent eyes FDA rolling submission in crowded lung cancer niche

By Angus Liu

While three Big Pharma companies have yet to successfully crack the ROS1 lung cancer market, young biotech Nuvalent believes competitive pivotal data from its investigational drug are paving the way to a quick FDA filing and, eventually, a chance at a major opportunity.

BrightGene tops Novo drug in diabetes ahead of Zepbound showdown

By Nick Paul Taylor

BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. The biotech linked its challenger to bigger reductions in blood sugar than Novo Nordisk’s semaglutide, giving momentum as it barrels toward a readout from a head-to-head trial against Eli Lilly’s tirzepatide.

UK lays out strategy to become a top 3 life sciences economy by 2035

By Zoey Becker

With a goal of boosting its life sciences economy into the top three of the global rankings by 2035, the U.K. government is laying out six specific areas of focus to bolster its growth in the industry.

FDA's acting CDER head Jacqueline Corrigan-Curay heads for the exit amid period of heavy turnover: reports

By Eric Sagonowsky

Only a few days after reports emerged that the director of the FDA's cell and gene therapy office had been abruptly put on administrative leave, a new departure shows an intense period of leadership turnover at the agency isn't over.

Cassidy, key in RFK Jr.'s HHS confirmation, calls for deferral of CDC's vaccine meeting

By Angus Liu

Sen. Bill Cassidy, M.D., R-La., has come out critical of Robert F. Kennedy Jr.’s picks for the CDC’s vaccine advisory panel, calling for the committee’s upcoming meeting to be postponed.

Fierce podcasts

Don’t miss an episode

AbbVie, ADCs and the future of cancer care

This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates.

A bold bet on sharing real-time patient data

Inside Fierce Medtech's Fierce 15

Resources

Executive Summary

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.